SynthesisBMC cancer2023

Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials.

Shu-Ling Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.